Boule Diagnostics
Interim Report
Q1 2021
About Boule Diagnostics
Boule Diagnostics AB is a global diagnostics company specializing in near-patient, decentralized blood diagnostics and one of the few companies in the global diagnostics market that conducts its own development, manufacturing and marketing of instruments and consumables for blood diagnostics. The Company primarily serves hospitals, clinics, laboratories and other diagnostics companies.
Gradual recovery and increasing instrument sales
Sales growth points to increasing optimism as vaccination programs continue, with net sales adjusted for currency effect increasing by 12 percent from the previous quarter. However, net sales compared with Q1 2020 fell by 15 percent to SEK 101 million. Adjusted for currency effects, the decline was 6 percent.
The recovery has been strongest in the United States, where net sales in local currency grew by 6 percent. Several of our markets in Asia, notably India, have been affected by new virus outbreaks and restrictions that have slowed their recovery. Our sales of both reagents and instruments in Asia are significantly below normal volumes.
Financial Highlights
NET SALES, MSEK
101
GROSS MARGIN
44,4 %
OPERATING PROFIT, MSEK
6.8
OPERATIONAL CASH FLOW, MSEK
12.6
